InsidersTradesSigma
Total declarations
Company
▲ Purchases (20 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
20
Disclosed sells
0
T+90 hit rate
52%
T+90 mean return
+16.7%
Across 29 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Jones James, Director. Director active across 1 company, notably Cumberland Pharmaceuticals INC. In total, 35 reports have been published. Breakdown: 20 buys · 0 sell. Total volume traded: €2k. History available since 17 March 2021. The latest transaction was disclosed on 1 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations35 total
8 shares@ US$4.86Common StockSEC:0001628280-25-029854:0
Ideal exit: 26 Jan 2026 (T+270)
8 shares@ US$4.240.1% of flowCommon StockSEC:0001628280-25-024353:0
Ideal exit: 27 Dec 2025 (T+270)
10 shares@ US$5.540.2% of flowCommon StockSEC:0001628280-25-016743:0
Ideal exit: 28 Nov 2025 (T+270)
1,000 shares@ US$5.1720.9% of flowCommon StockSEC:0001628280-25-013544:0
2,500 shares@ US$1.7117.4% of flowCommon StockSEC:0001628280-25-003184:0
70 shares@ US$1.330.4% of flowCommon StockSEC:0001628280-24-052608:0
Ideal exit: 29 Aug 2025 (T+270)
76 shares@ US$1.150.4% of flowCommon StockSEC:0001628280-24-050111:0
Ideal exit: 29 Jul 2025 (T+270)
62 shares@ US$1.270.3% of flowCommon StockSEC:0001628280-24-045331:0
Ideal exit: 28 Jun 2025 (T+270)
50 shares@ US$1.380.3% of flowCommon StockSEC:0001628280-24-042120:0
44 shares@ US$1.470.3% of flowCommon StockSEC:0001214659-24-016020:0
44 shares@ US$1.470.3% of flowCommon StockSEC:0001214659-24-013687:0
25 shares@ US$1.520.2% of flowCommon StockSEC:0001214659-24-011869:0
1,000 shares@ US$1.717.0% of flowCommon StockSEC:0001214659-24-005224:0
72 shares@ US$1.690.5% of flowCommon StockSEC:0001214659-23-017035:0
55 shares@ US$1.850.4% of flowCommon StockSEC:0001214659-23-016101:0
55 shares@ US$1.890.4% of flowCommon StockSEC:0001214659-23-014542:0
65 shares@ US$1.680.4% of flowCommon StockSEC:0001214659-23-013094:0
65 shares@ US$1.640.4% of flowCommon StockSEC:0001214659-23-012223:0
1,000 shares@ US$1.978.0% of flowCommon StockSEC:0001209191-23-021266:0
31 shares@ US$2.330.3% of flowCommon StockSEC:0001209191-22-062654:0
Ideal exit: 28 Aug 2023 (T+270)
31 shares@ US$2.530.3% of flowCommon StockSEC:0001209191-22-062645:0
Ideal exit: 29 Jul 2023 (T+270)
31 shares@ US$2.570.4% of flowCommon StockSEC:0001209191-22-057945:0
Ideal exit: 24 Jun 2023 (T+270)
32 shares@ US$2.350.3% of flowCommon StockSEC:0001209191-22-051669:0
Ideal exit: 13 May 2023 (T+270)
30 shares@ US$2.110.3% of flowCommon StockSEC:0001209191-22-046898:0
Ideal exit: 28 Mar 2023 (T+270)
38 shares@ US$2.050.0001% mcap0.8% of flowCommon StockSEC:0001209191-22-040104:0
Ideal exit: 26 Feb 2023 (T+270)
25 of 35 declarations
About Jones James
James Jones is an executive at CUMBERLAND PHARMACEUTICALS INC.
